We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-5 of 5 results
  1. The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients

    Cancer is one of the main causes of mortality worldwide and a major public health concern. Among various strategies, therapeutic vaccines have been...

    Pierre Rosenbaum, Cécile Artaud, ... Claude Leclerc in Cancer Immunology, Immunotherapy
    Article 07 February 2020
  2. Novel classes of immunotherapy for breast cancer

    Immune-checkpoint inhibitors have profoundly changed the treatment landscape for many tumor types. Despite marked improvements in disease control for...

    Alberto Hernando-Calvo, David W. Cescon, Philippe L. Bedard in Breast Cancer Research and Treatment
    Article 08 October 2021
  3. Understanding Physico-chemical Interactions of Dendrimers with Guest Molecules for Efficient Drug and Gene Delivery

    Purpose of Review

    Drug and gene deliveries are crucial aspects in biomedical application as they stimulate biological response of the body to elicit a...

    Aishwarya Shetty, Priyal Chikhaliwala, ... Sudeshna Chandra in Current Pathobiology Reports
    Article 06 March 2021
  4. The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity

    Malignant transformations are often associated with aberrant glycosylation processes that lead to the expression of new carbohydrate antigens at the...

    Daphné Laubreton, Sylvie Bay, ... Claude Leclerc in Cancer Immunology, Immunotherapy
    Article Open access 04 February 2016
  5. Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer

    The Tn antigen (GalNAcα- O -Ser/Thr) is a well-established tumor-associated marker which represents a good target for the design of anti-tumor...

    Daniel Mazal, Richard Lo-Man, ... Eduardo Osinaga in Cancer Immunology, Immunotherapy
    Article 21 April 2013
Did you find what you were looking for? Share feedback.